Review



human pdl 1 to hpd1 25 167  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
      Buy from Supplier

    Structured Review

    Bio-Rad human pdl 1 to hpd1 25 167
    Characterization of hPD1(25-167)-His and hPD1(25-167)-3S-IG
    Human Pdl 1 To Hpd1 25 167, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 85/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdl+1+to+hpd1+25+167/pmc04476994-241-2-26?v=Bio-Rad
    Average 85 stars, based on 5 article reviews
    human pdl 1 to hpd1 25 167 - by Bioz Stars, 2026-07
    85/100 stars

    Images

    1) Product Images from "Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay"

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    Journal: The AAPS Journal

    doi: 10.1208/s12248-015-9762-4

    Characterization of hPD1(25-167)-His and hPD1(25-167)-3S-IG
    Figure Legend Snippet: Characterization of hPD1(25-167)-His and hPD1(25-167)-3S-IG

    Techniques Used:

    a–c Characterization of the assay reference standard-recombinant hPD1(25-167)-His protein. a SDS-PAGE analysis of the purified hPD1(25-167)-His protein expressed in HEK293 cells. Lane 1: molecular weight marker, lane 2: blank, lane 3: 1 μg of the purified hPD1(25-167)-His protein. The gel was stained with Simply Blue SafeStain. b Concentration series of hPDL-1 (0.125–2 μM) binding to captured hPD1(25-167)-His protein. c Equilibrium analysis of hPDL-1 binding to hPD1(25-167)-His yields a K D of 2.8 μM (average value over multiple surfaces)
    Figure Legend Snippet: a–c Characterization of the assay reference standard-recombinant hPD1(25-167)-His protein. a SDS-PAGE analysis of the purified hPD1(25-167)-His protein expressed in HEK293 cells. Lane 1: molecular weight marker, lane 2: blank, lane 3: 1 μg of the purified hPD1(25-167)-His protein. The gel was stained with Simply Blue SafeStain. b Concentration series of hPDL-1 (0.125–2 μM) binding to captured hPD1(25-167)-His protein. c Equilibrium analysis of hPDL-1 binding to hPD1(25-167)-His yields a K D of 2.8 μM (average value over multiple surfaces)

    Techniques Used: Recombinant, SDS Page, Purification, Molecular Weight, Marker, Staining, Concentration Assay, Binding Assay

    Binding Affinity of Anti-PD-1 Antibody MIH4 for Recombinant Human sPD-1 Proteins
    Figure Legend Snippet: Binding Affinity of Anti-PD-1 Antibody MIH4 for Recombinant Human sPD-1 Proteins

    Techniques Used: Binding Assay, Recombinant

    a–b Detection of endogenous sPD-1 protein and spike recovery in sera from normal and cancer individuals. a Levels of sPD-1 in serum samples from normal and cancer individuals: normal, n = 15; melanoma, n = 15; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. b Spike and recovery study: 500 pg/mL hPD1(25-167)-His protein was spiked into serum samples from normal and cancer individuals: normal, n = 10; melanoma n = 8; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. % Spike recovery = 100*(sample value post-spike − sample value pre-spike)/spiked value. Results are shown with box and whiskers graphs. The box included data within 5 to 95 percentiles with the median line in the middle and extended values in the whiskers. The dotted lines depict the nominal spiked value ± 25%
    Figure Legend Snippet: a–b Detection of endogenous sPD-1 protein and spike recovery in sera from normal and cancer individuals. a Levels of sPD-1 in serum samples from normal and cancer individuals: normal, n = 15; melanoma, n = 15; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. b Spike and recovery study: 500 pg/mL hPD1(25-167)-His protein was spiked into serum samples from normal and cancer individuals: normal, n = 10; melanoma n = 8; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. % Spike recovery = 100*(sample value post-spike − sample value pre-spike)/spiked value. Results are shown with box and whiskers graphs. The box included data within 5 to 95 percentiles with the median line in the middle and extended values in the whiskers. The dotted lines depict the nominal spiked value ± 25%

    Techniques Used:

    a–b Dilution linearity studies in melanoma and spiked normal sera. a Three melanoma serum samples (M1, M2, M3) were each diluted 1.5–8-fold with assay buffer; recombinant hPD1(25-167)-His protein standard in a SeraSub solution was diluted in same concentration range. b Three normal human serum samples (N1, N2, N3) were spiked with 5000 pg/mL of human hPD1(25-167)-His and were each diluted 2–256-fold with assay buffer. The back-calculated sPD-1 concentrations (observed concentrations times the dilution factor) were plotted against dilution factors. The dotted lines depict 75–125% range of the nominal spiked value
    Figure Legend Snippet: a–b Dilution linearity studies in melanoma and spiked normal sera. a Three melanoma serum samples (M1, M2, M3) were each diluted 1.5–8-fold with assay buffer; recombinant hPD1(25-167)-His protein standard in a SeraSub solution was diluted in same concentration range. b Three normal human serum samples (N1, N2, N3) were spiked with 5000 pg/mL of human hPD1(25-167)-His and were each diluted 2–256-fold with assay buffer. The back-calculated sPD-1 concentrations (observed concentrations times the dilution factor) were plotted against dilution factors. The dotted lines depict 75–125% range of the nominal spiked value

    Techniques Used: Recombinant, Concentration Assay

    a–b Effect of PDL-1, PDL-2, and nivolumab on QC sample performance. a sPD-1 in a melanoma serum sample measured in the absence or presence of 20 nM (1 μg/mL) of human PDL-1 or PDL-2 proteins. b QC performance from analytical runs in the absence or presence of 685 nM (100 μg/mL) nivolumab. Results are shown as mean and SD of each group (n = 2–4)
    Figure Legend Snippet: a–b Effect of PDL-1, PDL-2, and nivolumab on QC sample performance. a sPD-1 in a melanoma serum sample measured in the absence or presence of 20 nM (1 μg/mL) of human PDL-1 or PDL-2 proteins. b QC performance from analytical runs in the absence or presence of 685 nM (100 μg/mL) nivolumab. Results are shown as mean and SD of each group (n = 2–4)

    Techniques Used:



    Similar Products

    human pdl 1 to hpd1 25 167  (Bio-Rad)
    85
    Bio-Rad human pdl 1 to hpd1 25 167
    Characterization of hPD1(25-167)-His and hPD1(25-167)-3S-IG
    Human Pdl 1 To Hpd1 25 167, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdl+1+to+hpd1+25+167/pmc04476994-241-2-26?v=Bio-Rad
    Average 85 stars, based on 1 article reviews
    human pdl 1 to hpd1 25 167 - by Bioz Stars, 2026-07
    85/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterization of hPD1(25-167)-His and hPD1(25-167)-3S-IG

    Journal: The AAPS Journal

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    doi: 10.1208/s12248-015-9762-4

    Figure Lengend Snippet: Characterization of hPD1(25-167)-His and hPD1(25-167)-3S-IG

    Article Snippet: Binding of Human PDL-1 to hPD1(25-167)-His Surface plasmon resonance (SPR) experiments to characterize the binding of hPDL-1 to hPD1(25-167)-His were performed using a ProteOn XPR36 instrument (BioRad, Hercules, CA, USA).

    Techniques:

    a–c Characterization of the assay reference standard-recombinant hPD1(25-167)-His protein. a SDS-PAGE analysis of the purified hPD1(25-167)-His protein expressed in HEK293 cells. Lane 1: molecular weight marker, lane 2: blank, lane 3: 1 μg of the purified hPD1(25-167)-His protein. The gel was stained with Simply Blue SafeStain. b Concentration series of hPDL-1 (0.125–2 μM) binding to captured hPD1(25-167)-His protein. c Equilibrium analysis of hPDL-1 binding to hPD1(25-167)-His yields a K D of 2.8 μM (average value over multiple surfaces)

    Journal: The AAPS Journal

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    doi: 10.1208/s12248-015-9762-4

    Figure Lengend Snippet: a–c Characterization of the assay reference standard-recombinant hPD1(25-167)-His protein. a SDS-PAGE analysis of the purified hPD1(25-167)-His protein expressed in HEK293 cells. Lane 1: molecular weight marker, lane 2: blank, lane 3: 1 μg of the purified hPD1(25-167)-His protein. The gel was stained with Simply Blue SafeStain. b Concentration series of hPDL-1 (0.125–2 μM) binding to captured hPD1(25-167)-His protein. c Equilibrium analysis of hPDL-1 binding to hPD1(25-167)-His yields a K D of 2.8 μM (average value over multiple surfaces)

    Article Snippet: Binding of Human PDL-1 to hPD1(25-167)-His Surface plasmon resonance (SPR) experiments to characterize the binding of hPDL-1 to hPD1(25-167)-His were performed using a ProteOn XPR36 instrument (BioRad, Hercules, CA, USA).

    Techniques: Recombinant, SDS Page, Purification, Molecular Weight, Marker, Staining, Concentration Assay, Binding Assay

    Binding Affinity of Anti-PD-1 Antibody MIH4 for Recombinant Human sPD-1 Proteins

    Journal: The AAPS Journal

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    doi: 10.1208/s12248-015-9762-4

    Figure Lengend Snippet: Binding Affinity of Anti-PD-1 Antibody MIH4 for Recombinant Human sPD-1 Proteins

    Article Snippet: Binding of Human PDL-1 to hPD1(25-167)-His Surface plasmon resonance (SPR) experiments to characterize the binding of hPDL-1 to hPD1(25-167)-His were performed using a ProteOn XPR36 instrument (BioRad, Hercules, CA, USA).

    Techniques: Binding Assay, Recombinant

    a–b Detection of endogenous sPD-1 protein and spike recovery in sera from normal and cancer individuals. a Levels of sPD-1 in serum samples from normal and cancer individuals: normal, n = 15; melanoma, n = 15; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. b Spike and recovery study: 500 pg/mL hPD1(25-167)-His protein was spiked into serum samples from normal and cancer individuals: normal, n = 10; melanoma n = 8; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. % Spike recovery = 100*(sample value post-spike − sample value pre-spike)/spiked value. Results are shown with box and whiskers graphs. The box included data within 5 to 95 percentiles with the median line in the middle and extended values in the whiskers. The dotted lines depict the nominal spiked value ± 25%

    Journal: The AAPS Journal

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    doi: 10.1208/s12248-015-9762-4

    Figure Lengend Snippet: a–b Detection of endogenous sPD-1 protein and spike recovery in sera from normal and cancer individuals. a Levels of sPD-1 in serum samples from normal and cancer individuals: normal, n = 15; melanoma, n = 15; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. b Spike and recovery study: 500 pg/mL hPD1(25-167)-His protein was spiked into serum samples from normal and cancer individuals: normal, n = 10; melanoma n = 8; renal cell carcinoma, n = 11; squamous lung cancer, n = 7; non-squamous lung cancer, n = 8; multiple myeloma, n = 10; Hodgkin’s lymphoma, n = 7. % Spike recovery = 100*(sample value post-spike − sample value pre-spike)/spiked value. Results are shown with box and whiskers graphs. The box included data within 5 to 95 percentiles with the median line in the middle and extended values in the whiskers. The dotted lines depict the nominal spiked value ± 25%

    Article Snippet: Binding of Human PDL-1 to hPD1(25-167)-His Surface plasmon resonance (SPR) experiments to characterize the binding of hPDL-1 to hPD1(25-167)-His were performed using a ProteOn XPR36 instrument (BioRad, Hercules, CA, USA).

    Techniques:

    a–b Dilution linearity studies in melanoma and spiked normal sera. a Three melanoma serum samples (M1, M2, M3) were each diluted 1.5–8-fold with assay buffer; recombinant hPD1(25-167)-His protein standard in a SeraSub solution was diluted in same concentration range. b Three normal human serum samples (N1, N2, N3) were spiked with 5000 pg/mL of human hPD1(25-167)-His and were each diluted 2–256-fold with assay buffer. The back-calculated sPD-1 concentrations (observed concentrations times the dilution factor) were plotted against dilution factors. The dotted lines depict 75–125% range of the nominal spiked value

    Journal: The AAPS Journal

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    doi: 10.1208/s12248-015-9762-4

    Figure Lengend Snippet: a–b Dilution linearity studies in melanoma and spiked normal sera. a Three melanoma serum samples (M1, M2, M3) were each diluted 1.5–8-fold with assay buffer; recombinant hPD1(25-167)-His protein standard in a SeraSub solution was diluted in same concentration range. b Three normal human serum samples (N1, N2, N3) were spiked with 5000 pg/mL of human hPD1(25-167)-His and were each diluted 2–256-fold with assay buffer. The back-calculated sPD-1 concentrations (observed concentrations times the dilution factor) were plotted against dilution factors. The dotted lines depict 75–125% range of the nominal spiked value

    Article Snippet: Binding of Human PDL-1 to hPD1(25-167)-His Surface plasmon resonance (SPR) experiments to characterize the binding of hPDL-1 to hPD1(25-167)-His were performed using a ProteOn XPR36 instrument (BioRad, Hercules, CA, USA).

    Techniques: Recombinant, Concentration Assay

    a–b Effect of PDL-1, PDL-2, and nivolumab on QC sample performance. a sPD-1 in a melanoma serum sample measured in the absence or presence of 20 nM (1 μg/mL) of human PDL-1 or PDL-2 proteins. b QC performance from analytical runs in the absence or presence of 685 nM (100 μg/mL) nivolumab. Results are shown as mean and SD of each group (n = 2–4)

    Journal: The AAPS Journal

    Article Title: Development and Fit-for-Purpose Validation of a Soluble Human Programmed Death-1 Protein Assay

    doi: 10.1208/s12248-015-9762-4

    Figure Lengend Snippet: a–b Effect of PDL-1, PDL-2, and nivolumab on QC sample performance. a sPD-1 in a melanoma serum sample measured in the absence or presence of 20 nM (1 μg/mL) of human PDL-1 or PDL-2 proteins. b QC performance from analytical runs in the absence or presence of 685 nM (100 μg/mL) nivolumab. Results are shown as mean and SD of each group (n = 2–4)

    Article Snippet: Binding of Human PDL-1 to hPD1(25-167)-His Surface plasmon resonance (SPR) experiments to characterize the binding of hPDL-1 to hPD1(25-167)-His were performed using a ProteOn XPR36 instrument (BioRad, Hercules, CA, USA).

    Techniques: